• Suzanne C Dixon, Christina M Nagle, Nicolas Wentzensen, Britton Trabert, Alicia Beeghly-Fadiel, Joellen M Schildkraut, Kirsten B Moysich, Anna deFazio, Australian Ovarian Cancer Study Group, Harvey A Risch, Mary Anne Rossing, Jennifer A Doherty, Kristine G Wicklund, Marc T Goodman, Francesmary Modugno, Roberta B Ness, Robert P Edwards, Allan Jensen, Susanne K Kjær, Estrid Høgdall, Andrew Berchuck, Daniel W Cramer, Kathryn L Terry, Elizabeth M Poole, Elisa V Bandera, Lisa E Paddock, Hoda Anton-Culver, Argyrios Ziogas, Usha Menon, Simon A Gayther, Susan J Ramus, Aleksandra Gentry-Maharaj, Celeste Leigh Pearce, Anna H Wu, Malcolm C Pike, and Penelope M Webb.
• Gynaecological Cancers Group, QIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, Queensland 4006, Australia.
• Br. J. Cancer. 2017 Apr 25; 116 (9): 1223-1228.

BackgroundNonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with improved survival in some cancers, but evidence for ovarian cancer is limited.MethodsPooling individual-level data from 12 Ovarian Cancer Association Consortium studies, we evaluated the association between self-reported, pre-diagnosis use of common analgesics and overall/progression-free/disease-specific survival among 7694 women with invasive epithelial ovarian cancer (4273 deaths).ResultsRegular analgesic use (at least once per week) was not associated with overall survival (pooled hazard ratios, pHRs (95% confidence intervals): aspirin 0.96 (0.88-1.04); non-aspirin NSAIDs 0.97 (0.89-1.05); acetaminophen 1.01 (0.93-1.10)), nor with progression-free/disease-specific survival. There was however a survival advantage for users of any NSAIDs in studies clearly defining non-use as less than once per week (pHR=0.89 (0.82-0.98)).ConclusionsAlthough this study did not show a clear association between analgesic use and ovarian cancer survival, further investigation with clearer definitions of use and information about post-diagnosis use is warranted.

23 keywords...

hide…